Naslov
Stable gastric pentadecapeptide BPC 157 therapy for subdiaphragmatic occlusion of the suprahepatic inferior caval vein in rats

Autori
Gojković, Slaven ; Žižek, Helena ; Krezić, Ivan ; Malekinušić, Dominik ; Vrdoljak, Borna ; Antunović, Marko ; Drmić, Domagoj ; Horvat, Katarina ; Seiwerth, Sven ; Sikirić, Predrag

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Gastroenterology (New York, N.Y. 1943), 154 (2018), 6(S) / - , 2018, S-532

Skup
Digestive Disease Week

Mjesto i datum
Washington D.C., Sjedinjene Američke Države, 02.06.2018. - 05.06.2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
inferior caval vein occlusion ; BPC 157

Sažetak
Aim. This study concerns the stable gastric pentadecapeptide BPC 157 therapy for subdiaphragmatic occlusion of the suprahepatic inferior caval vein (SHIVC) in rats, immediate portal hypertension, and inferior caval vein (ICV) hypertension. L-NAME and L-arginine were also used. In general, after bile duct ligation, BPC 157-therapy counteracted perilous patterns of microscopy (smaller intensity of architectural changes (fibrosis and cirrhosis), lower necroinflammatory score, smaller α-SMA distribution) and gross presentation (jaundice, ascites, nodular, steatotic liver, bile duct dilatation, increased liver and/or cyst weight, body weight loss, in particular) along with decreased total bilirubin, direct and indirect, ALT, AST, GGT and preserved albumin serum values. (Gastroenterology 2014 ; 146, Issue 5, Supplement 1: S-882). Also, BPC 157-rats had no portal hypertension (J Physiol Paris. 2001 Jan-Dec ; 95(1-6):295-301). Methods. In anesthetized SHIVC- ligated rats, at 5 min ligation time, blood pressure recordings were obtained for over 20 min using a cannula (BD Neoflon™ Cannula) that was connected to a pressure transducer (78534C MONITOR/ TERMINAL Hewlett Packard) and was inserted in portal vein (PV) or in ICV. Given medication was bath (BPC 157 10 µg, 10 ng/kg/1ml bath/rat ; L- NAME 5 mg/kg/1ml bath/rat ; Larginine 100 mg/kg/1ml bath/rat, alone and/or together ; equivolume saline (controls)) into the abdominal cavity after 5 min of the blood pressure assessment, providing stable pressure values. In rats that underwent SHICV-ligation, respecting vein congestion upon SHICVligation (scored 0-3), presentation of ICV and superior mesenteric vein (SMV) was used to exhibit vessel change along with resolving of hypertension in PV and ICV. At the end of the pressure assessment relative spleen mass was taken. Results. Portal hypertension/ICV hypertension. Regularly rats underwent SHICV- ligation exhibit portal hypertension of 68±4 and ICV hypertension of 45±4 that both remain stable until the end. BPC 157. Both pressure values (mmHg) were normalized (3±1 (ug) ; 3±1(ng) portal pressure ; 5±1 (µg) ; 4±1(ng) ICV pressure). L- NAME and/or L-arginine. L-NAME produces an additional increase of portal and ICV pressure ; L-arginine produces a small decrease (48±4 portal ; 35±4 ICV) but completely abrogated BPC 157 effect. Given together (L- NAME+L-arginine) regularly antagonized each other's response, thus, NO-effect. With BPC 157, SHICV-ligated rats that received L-NAME (BPC 157+L-NAME) or L-NAME+L- arginine (BPC 157+L- NAME+L-arginine) showed values like rats that received BPC 157 alone. ICV and SMV were both severely congested, and this was completely eliminated by BPC 157 application (Fig. 1). BPC 157 also counteracted increase of the relative spleen mass. Conclusion. BPC 157 may be a useful therapy for subdiaphragmatic occlusion of the SHIVC in rats.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA